Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck licenses cancer drug from Eisai
by Michael McCoy
March 12, 2018
| A version of this story appeared in
Volume 96, Issue 11
Merck & Co. will pay Eisai $750 million plus milestone payments of up to $4 billion to jointly develop Eisai’s lenvatinib mesylate, a small-molecule tyrosine kinase inhibitor already approved to treat certain cancers. The two firms will develop the drug, sold as Lenvima, as a monotherapy and in combination with Merck’s Keytruda anti-PD-1 cancer therapy. “There is strong scientific evidence supporting synergistic effects of Keytruda when used in combination with Lenvima,” says Roger M. Perlmutter, president of Merck Research Laboratories.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter